


EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.
2. Authorization for this examiner's amendment was given in a telephone interview with Mr. Bernard Friedrichsen on September 3, 2010.
3. The application has been amended as follows:

A. In the specification, at page 27, paragraph [0216] has been amended to read as follows:

[0216] In certain embodiments, the present invention provides compounds according to formula **(IV)**:




IV

or a pharmaceutically acceptable salt, hydrate or prodrug thereof, wherein R²⁵, W, Y, and L are defined as in the preceding paragraph.

B. In the specification, at page 28, paragraph [0222] has been amended to read as follows:


[0222] In some embodiments, the present invention provides compounds according to formula (V):



or a pharmaceutically acceptable salt, hydrate or prodrug thereof, where R^{21} , R^{22} and W are defined as in the paragraph preceding that providing the structure of the compounds of formula IV.

C. In the specification, at page 29, paragraph [0230] has been amended to read as follows:


[0230] In certain embodiments, the present invention provides compounds according to formula (VI):



or a pharmaceutically acceptable salt, solvate or prodrug thereof, where R^{25} and W are defined in the paragraph preceding that providing the structure of the compounds of formula IV.

D. In the specification, at page 30, paragraph [0234] has been amended to read as follows:

[0234] In certain embodiments, the present invention provides compounds according to formula (VII):




VII

or a pharmaceutically acceptable salt, hydrate or prodrug thereof, wherein each R^{28} is independently selected from the group consisting of substituted or unsubstituted (C_1-C_{10}) alkyl, substituted or unsubstituted hetero (C_1-C_{10}) alkyl, substituted or unsubstituted halo (C_1-C_{10}) alkyl, substituted or unsubstituted aryl (C_1-C_{10}) alkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl, the subscript q is an integer from 0 to 5, and R^{25} is as defined above in the paragraph preceding that providing the structure of the compounds of formula IV.

E. In the specification, at page 31, paragraph [0241] has been amended to read as follows:

[0241] In certain embodiments, the present invention provides compounds according to formula (VIII):



VIII

or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein R^{21} , R^{22} and W are defined in the paragraph preceding that providing the structure of the compounds of formula IV and Ar and T are defined below.

REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance:

4. At pages 27-31 of the specification, the paragraphs have been amended to delete reference to paragraph [0215].
5. The changes made by Examiner's Amendment are editorial in nature.
6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Zinna Northington Davis whose telephone number is 571-272-0682. The examiner can normally be reached on M-F.
7. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
8. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Zinna Northington Davis/
Zinna Northington Davis
Primary Examiner
Art Unit 1625